Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Consensus Target Price from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $8.00.

A number of research analysts have weighed in on QNCX shares. Oppenheimer started coverage on Quince Therapeutics in a research note on Monday, March 24th. They set an “outperform” rating and a $10.00 price target on the stock. D. Boral Capital dropped their price objective on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, March 25th.

Institutional Trading of Quince Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in QNCX. Geode Capital Management LLC increased its holdings in shares of Quince Therapeutics by 24.2% during the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after buying an additional 66,170 shares during the last quarter. Scharf Investments LLC acquired a new stake in Quince Therapeutics in the 4th quarter valued at $170,000. Anfield Capital Management LLC acquired a new stake in Quince Therapeutics in the 4th quarter valued at $50,000. Virtu Financial LLC acquired a new stake in Quince Therapeutics in the 4th quarter valued at $55,000. Finally, Northern Trust Corp increased its holdings in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares in the last quarter. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Trading Down 1.0%

Shares of Quince Therapeutics stock opened at $1.02 on Wednesday. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The firm has a market cap of $45.01 million, a PE ratio of -0.82 and a beta of 0.83. The business’s fifty day moving average is $1.21 and its two-hundred day moving average is $1.52. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million during the quarter. Analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.